Insulin Regulation of Lipolysis and Lipolysis Proteins


About this study

The purpose of this study is to determine whether impaired insulin-induced suppression of lipolysis (as measured by IC50) is related to lipolysis proteins in groups of volunteers known to vary widely with regards to abdominal adipocyte size and regulation of adipose tissue lipolysis, and whether the improved insulin regulation of lipolysis resulting from treatment with the PPARγ agonist pioglitazone, with or without weight loss, can be linked to specific changes in sets of PPARγ-responsive adipocyte lipolysis proteins in UBO adults.






Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Lower body obesity (LBO) premenopausal women and 6 healthy, age-matched lower body obesity (LBO) men will be recruited as the “insulin sensitive” obese group
  • 20 upper body/visceral obesity (UBO) premenopausal women and 20 age-matched upper body/visceral obesity (UBO) men will serve as the insulin resistant group 
  • 6 healthy, age matched normal weight men and women will serve as the lean control group.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Michael Jensen, M.D.

Open for enrollment

Contact information:

Pamela Reich

(507) 255-6062

More information


Publications are currently not available

Mayo Clinic Footer